Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Evidence for a Common Pharmacological Interaction Site on KCa2 Channels Providing Both Selective Activation and Selective Inhibition of the Human KCa2.1 Subtype

Charlotte Hougaard, Sofia Hammami, Birgitte L. Eriksen, Ulrik S. Sørensen, Marianne L. Jensen, Dorte Strøbæk and Palle Christophersen
Molecular Pharmacology February 2012, 81 (2) 210-219; DOI: https://doi.org/10.1124/mol.111.074252
Charlotte Hougaard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sofia Hammami
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Birgitte L. Eriksen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrik S. Sørensen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianne L. Jensen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorte Strøbæk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Palle Christophersen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

We have previously identified Ser293 in transmembrane segment 5 as a determinant for selective KCa2.1 channel activation by GW542573X (4-(2-methoxyphenylcarbamoyloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester). Now we show that Ser293 mediates both activation and inhibition of KCa2.1: CM-TPMF (N-{7-[1-(4-chloro-2-methylphenoxy)ethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-N′-methoxy-formamidine) and B-TPMF (N-{7-[1-(4-tert-butyl-phenoxy)ethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-N′-methoxy-formamidine), two newly identified and structurally related [1,2,4]triazolo[1,5-a]pyrimidines, act either as activators or as inhibitors of the human KCa2.1 channel. Whereas (−)-CM-TPMF activates KCa2.1 with an EC50 value of 24 nM, (−)-B-TPMF inhibits the channel with an IC50 value of 31 nM. In contrast, their (+)-enantiomers are 40 to 100 times less active. Both (−)-CM-TPMF and (−)-B-TPMF are subtype-selective, with 10- to 20-fold discrimination toward other KCa2 channels and the KCa3 channel. Coapplication experiments reveal competitive-like functional interactions between the effects of (−)-CM-TPMF and (−)-B-TPMF. Despite belonging to a different chemical class than GW542573X, the KCa2.1 selectivity of (−)-CM-TPMF and (−)-B-TPMF depend critically on Ser293 as revealed by loss- and gain-of-function mutations. We conclude that compounds occupying the TPMF site may either positively or negatively influence the gating process depending on their substitution patterns. It is noteworthy that (−)-CM-TPMF is 10 times more potent on KCa2.1 than NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime), an unselective but hitherto the most potent KCa3/KCa2 channel activator. (−)-B-TPMF is the first small-molecule inhibitor with significant selectivity among the KCa2 channel subtypes. In contrast to peptide blockers such as apamin and scyllatoxin, which preferentially affect KCa2.2, (−)-B-TPMF exhibits KCa2.1 selectivity. These high-affinity compounds, which exert opposite effects on KCa2.1 gating, may help define physiological or pathophysiological roles of this channel.

Footnotes

  • Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

    http://dx.doi.org/10.1124/mol.111.074252.

  • ABBREVIATIONS:

    KCNN
    small and intermediate conductance Ca2+-activated K+ channel
    CaM
    calmodulin
    CaMBD
    CaM binding domain
    CNS
    central nervous system
    1-EBIO
    1-ethyl-2-benzimidazolinone
    UCL1684
    6,10-diaza-3(1,3),8(1,4)-dibenzena-1,5(1,4)-diquinolinacyclodecaphane
    DCEBIO
    5,6-dichloro-1-ethyl-1,3-dihydro-2H-benzimidazol-2-one
    NS4591
    4,5-dichloro-1,3-diethyl-2,3-dihydro-1H-1,3-benzodiazol-2-one
    SKA-31
    naphtho[1,2-d]thiazol-2-ylamine
    NS8593
    (R)-N-(benzimidazol-2-yl)-tetrahydro-1-naphtylamine
    NS309
    6,7-dichloro-1H-indole-2,3-dione 3-oxime
    GW542573X
    4-(2-methoxyphenylcarbamoyloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester
    B-TPMF
    (N-{7-[1-(4-tert-butyl-phenoxy)ethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-N′-methoxy-formamidine
    CM-TPMF
    N-{7-[1-(4-chloro-2-methylphenoxy)ethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-N′-methoxy-formamidine
    1-EBIO
    1-ethyl-2-benzimidazolinone
    HEK
    human embryonic kidney
    I-V
    current-voltage
    Bay-k-8644
    S-(−)-1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-[trifluoromethyl]phenyl)-3-pyridine carboxylic acid methyl ester
    KCa2
    small conductance Ca2+-activated K+ channel (SK channel)
    KCa3.1
    intermediate conductance Ca2+-activated K+ channel (IK channel).

  • Received June 22, 2011.
  • Accepted November 1, 2011.
  • Copyright © 2012 The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 81 (2)
Molecular Pharmacology
Vol. 81, Issue 2
1 Feb 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Evidence for a Common Pharmacological Interaction Site on KCa2 Channels Providing Both Selective Activation and Selective Inhibition of the Human KCa2.1 Subtype
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Positive and Negative Gating Modulation of KCa2.1

Charlotte Hougaard, Sofia Hammami, Birgitte L. Eriksen, Ulrik S. Sørensen, Marianne L. Jensen, Dorte Strøbæk and Palle Christophersen
Molecular Pharmacology February 1, 2012, 81 (2) 210-219; DOI: https://doi.org/10.1124/mol.111.074252

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Positive and Negative Gating Modulation of KCa2.1

Charlotte Hougaard, Sofia Hammami, Birgitte L. Eriksen, Ulrik S. Sørensen, Marianne L. Jensen, Dorte Strøbæk and Palle Christophersen
Molecular Pharmacology February 1, 2012, 81 (2) 210-219; DOI: https://doi.org/10.1124/mol.111.074252
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cysteine151 in Keap1 Drives CDDO-Me Pharmacodynamic Action
  • Allosteric Modulation of Metabotropic Glutamate Receptor 1
  • Mechanism of Selective Action of Paraherquamide A
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics